

Hiroyoshi Nishikawa

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/748261/publications.pdf>

Version: 2024-02-01

136
papers

17,314
citations

44069

48
h-index

16183

124
g-index

143
all docs

143
docs citations

143
times ranked

23755
citing authors

#	ARTICLE	IF	CITATIONS
1	Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota. <i>Nature</i> , 2013, 500, 232-236.	27.8	2,339
2	Intraepithelial CD8 ⁺ tumor-infiltrating lymphocytes and a high CD8 ⁺ /regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 18538-18543.	7.1	2,100
3	Regulatory T cells in cancer immunosuppression – implications for anticancer therapy. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 356-371.	27.6	872
4	Regulatory T cells in tumor immunity. <i>International Journal of Cancer</i> , 2010, 127, 759-767.	5.1	749
5	PD-1 ⁺ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9999-10008.	7.1	655
6	Two FOXP3 ⁺ CD4 ⁺ T cell subpopulations distinctly control the prognosis of colorectal cancers. <i>Nature Medicine</i> , 2016, 22, 679-684.	30.7	641
7	Regulatory T (Treg) cells in cancer: Can Treg cells be a new therapeutic target?. <i>Cancer Science</i> , 2019, 110, 2080-2089.	3.9	614
8	Regulatory T cells in cancer immunotherapy. <i>Current Opinion in Immunology</i> , 2014, 27, 1-7.	5.5	612
9	Anti-CCR4 mAb selectively depletes effector-type FoxP3 ⁺ CD4 ⁺ regulatory T cells, evoking antitumor immune responses in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 17945-17950.	7.1	556
10	Regorafenib Plus Nivolumab in Patients With Advanced Gastric or Colorectal Cancer: An Open-Label, Dose-Escalation, and Dose-Expansion Phase Ib Trial (REGONIVO, EPOC1603). <i>Journal of Clinical Oncology</i> , 2020, 38, 2053-2061.	1.6	469
11	Interleukin-10-Producing Plasmablasts Exert Regulatory Function in Autoimmune Inflammation. <i>Immunity</i> , 2014, 41, 1040-1051.	14.3	450
12	The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. <i>Nature Immunology</i> , 2020, 21, 1346-1358.	14.5	431
13	Roles of regulatory T cells in cancer immunity. <i>International Immunology</i> , 2016, 28, 401-409.	4.0	412
14	NY-ESO-1: Review of an Immunogenic Tumor Antigen. <i>Advances in Cancer Research</i> , 2006, 95, 1-30.	5.0	311
15	Fecal microbiota transplantation for patients with steroid-resistant acute graft-versus-host disease of the gut. <i>Blood</i> , 2016, 128, 2083-2088.	1.4	279
16	Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments. <i>Cancer Cell</i> , 2022, 40, 201-218.e9.	16.8	266
17	Natural and Induced T Regulatory Cells in Cancer. <i>Frontiers in Immunology</i> , 2013, 4, 190.	4.8	202
18	Tumor-infiltrating IL-17A-producing T cells support the progression of tumor by promoting angiogenesis. <i>European Journal of Immunology</i> , 2010, 40, 1927-1937.	2.9	200

#	ARTICLE	IF	CITATIONS
19	Phase Ia Study of FoxP3+ CD4 Treg Depletion by Infusion of a Humanized Anti-CCR4 Antibody, KW-0761, in Cancer Patients. <i>Clinical Cancer Research</i> , 2015, 21, 4327-4336.	7.0	187
20	Regulatory T cells: a potential target in cancer immunotherapy. <i>Annals of the New York Academy of Sciences</i> , 2018, 1417, 104-115.	3.8	184
21	Sialyl Lewis x (CD15s) identifies highly differentiated and most suppressive FOXP3 ^{high} regulatory T cells in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 7225-7230.	7.1	164
22	In vivo antigen delivery by a <i>Salmonella typhimurium</i> type III secretion system for therapeutic cancer vaccines. <i>Journal of Clinical Investigation</i> , 2006, 116, 1946-1954.	8.2	164
23	Detection of self-reactive CD8 ⁺ T cells with an anergic phenotype in healthy individuals. <i>Science</i> , 2014, 346, 1536-1540.	12.6	162
24	CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients. <i>Blood</i> , 2005, 106, 1008-1011.	1.4	160
25	Blockade of EGFR improves responsiveness to PD-1 blockade in EGFR-mutated non-small cell lung cancer. <i>Science Immunology</i> , 2020, 5, .	11.9	160
26	CD4+ CD25+ T cells responding to serologically defined autoantigens suppress antitumor immune responses. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003, 100, 10902-10906.	7.1	152
27	Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti-CTLA-4 antibody. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 609-618.	7.1	141
28	Antitumour immunity regulated by aberrant ERBB family signalling. <i>Nature Reviews Cancer</i> , 2021, 21, 181-197.	28.4	141
29	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment. , 2018, 6, 106.		138
30	Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2019, 39, 165-174.	3.8	123
31	An Oncogenic Alteration Creates a Microenvironment that Promotes Tumor Progression by Conferring a Metabolic Advantage to Regulatory T Cells. <i>Immunity</i> , 2020, 53, 187-203.e8.	14.3	119
32	Definition of target antigens for naturally occurring CD4+ CD25+ regulatory T cells. <i>Journal of Experimental Medicine</i> , 2005, 201, 681-686.	8.5	118
33	Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals. <i>Clinical Cancer Research</i> , 2010, 16, 2781-2791.	7.0	118
34	A Phase I Study of the Anti-CC Chemokine Receptor 4 Antibody, Mogamulizumab, in Combination with Nivolumab in Patients with Advanced or Metastatic Solid Tumors. <i>Clinical Cancer Research</i> , 2019, 25, 6614-6622.	7.0	106
35	Mechanisms of regulatory T cell infiltration in tumors: implications for innovative immune precision therapies. , 2021, 9, e002591.		105
36	Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2005, 102, 9253-9257.	7.1	102

#	ARTICLE	IF	CITATIONS
37	ICOS ⁺ Foxp3 ⁺ TILs in gastric cancer are prognostic markers and effector regulatory T cells associated with <i>Helicobacter pylori</i> . <i>International Journal of Cancer</i> , 2017, 140, 686-695.	5.1	100
38	IFN- γ Controls the Generation/Activation of CD4 ⁺ CD25 ⁺ Regulatory T Cells in Antitumor Immune Response. <i>Journal of Immunology</i> , 2005, 175, 4433-4440.	0.8	92
39	Detection of T cell responses to a ubiquitous cellular protein in autoimmune disease. <i>Science</i> , 2014, 346, 363-368.	12.6	86
40	Selective inhibition of low-affinity memory CD8 ⁺ T cells by corticosteroids. <i>Journal of Experimental Medicine</i> , 2019, 216, 2701-2713.	8.5	82
41	Regulatory T Cell-Resistant CD8 ⁺ T Cells Induced by Glucocorticoid-Induced Tumor Necrosis Factor Receptor Signaling. <i>Cancer Research</i> , 2008, 68, 5948-5954.	0.9	80
42	The critical role of CD4 ⁺ T cells in PD-1 blockade against MHC-II ⁺ expressing tumors such as classic Hodgkin lymphoma. <i>Blood Advances</i> , 2020, 4, 4069-4082.	5.2	76
43	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4 ⁺ T cells in patients with malignant melanoma. <i>International Immunology</i> , 2018, 30, 13-22.	4.0	74
44	Immune Suppression by PD-L2 against Spontaneous and Treatment-Related Antitumor Immunity. <i>Clinical Cancer Research</i> , 2019, 25, 4808-4819.	7.0	66
45	Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma. <i>Blood</i> , 2012, 119, 3097-3104.	1.4	65
46	Highly immunogenic cancer cells require activation of the WNT pathway for immunological escape. <i>Science Immunology</i> , 2021, 6, eabc6424.	11.9	64
47	Preoperative Chemoradiotherapy plus Nivolumab before Surgery in Patients with Microsatellite Stable and Microsatellite Instability-High Locally Advanced Rectal Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 1136-1146.	7.0	62
48	Treatment-free remission after two-year consolidation therapy with nilotinib in patients with chronic myeloid leukemia: STAT2 trial in Japan. <i>Haematologica</i> , 2018, 103, 1835-1842.	3.5	59
49	Tyrosine kinase inhibitor imatinib augments tumor immunity by depleting effector regulatory T cells. <i>Journal of Experimental Medicine</i> , 2020, 217, .	8.5	58
50	Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor β 2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele. <i>Cytotherapy</i> , 2012, 14, 733-742.	0.7	56
51	Influence of CD4 ⁺ CD25 ⁺ Regulatory T Cells on Low/High-Avidity CD4 ⁺ T Cells following Peptide Vaccination. <i>Journal of Immunology</i> , 2006, 176, 6340-6346.	0.8	52
52	NYA-CO-58/KIF2C is overexpressed in a variety of solid tumors and induces frequent T cell responses in patients with colorectal cancer. <i>International Journal of Cancer</i> , 2010, 127, 381-393.	5.1	52
53	Transcriptional regulatory network for the establishment of CD8 ⁺ T cell exhaustion. <i>Experimental and Molecular Medicine</i> , 2021, 53, 202-209.	7.7	51
54	Regulatory T Cells: Molecular and Cellular Basis for Immunoregulation. <i>Current Topics in Microbiology and Immunology</i> , 2017, 410, 3-27.	1.1	48

#	ARTICLE	IF	CITATIONS
55	Clinical impact of pre-transplant gut microbial diversity on outcomes of allogeneic hematopoietic stem cell transplantation. <i>Annals of Hematology</i> , 2017, 96, 1517-1523.	1.8	48
56	Peptide Vaccine Induces Enhanced Tumor Growth Associated with Apoptosis Induction in CD8+ T Cells. <i>Journal of Immunology</i> , 2010, 185, 3768-3776.	0.8	47
57	CD4 ⁺ T cells are essential for the development of destructive thyroiditis induced by anti- α -PD-1 antibody in thyroglobulin-immunized mice. <i>Science Translational Medicine</i> , 2021, 13, .	12.4	47
58	A mixture-of-experts deep generative model for integrated analysis of single-cell multiomics data. <i>Cell Reports Methods</i> , 2021, 1, 100071.	2.9	47
59	Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy. <i>Cancer Research</i> , 2012, 72, 1672-1682.	0.9	46
60	Clinicopathological features of 22C3 PD-L1 expression with mismatch repair, Epstein-Barr virus status, and cancer genome alterations in metastatic gastric cancer. <i>Gastric Cancer</i> , 2019, 22, 69-76.	5.3	45
61	PD-1 blockade therapy promotes infiltration of tumor-attacking exhausted T cell clonotypes. <i>Cell Reports</i> , 2022, 38, 110331.	6.4	45
62	Multicenter Phase I/II Trial of Napabucasin and Pembrolizumab in Patients with Metastatic Colorectal Cancer (EPOC1503/SCOOP Trial). <i>Clinical Cancer Research</i> , 2020, 26, 5887-5894.	7.0	44
63	The Soluble Notch Ligand, Jagged-1, Inhibits Proliferation of CD34+ Macrophage Progenitors. <i>International Journal of Hematology</i> , 2002, 75, 269-276.	1.6	40
64	Vaginal Transmission of Cancer from Mothers with Cervical Cancer to Infants. <i>New England Journal of Medicine</i> , 2021, 384, 42-50.	27.0	40
65	Heteroclitic serological response in esophageal and prostate cancer patients after NY-ESO-1 protein vaccination. <i>International Journal of Cancer</i> , 2012, 130, 584-592.	5.1	38
66	Thioredoxin suppresses airway inflammation independently of systemic Th1/Th2 immune modulation. <i>European Journal of Immunology</i> , 2010, 40, 787-796.	2.9	37
67	Identification of Tumoricidal TCRs from Tumor-Infiltrating Lymphocytes by Single-Cell Analysis. <i>Cancer Immunology Research</i> , 2018, 6, 378-388.	3.4	35
68	Glucocorticoid-induced tumor necrosis factor receptor stimulation enhances the multifunctionality of adoptively transferred tumor antigen-specific CD8 ⁺ T cells with tumor regression. <i>Cancer Science</i> , 2009, 100, 1317-1325.	3.9	34
69	IFN- γ -dependent type 1 immunity is crucial for immunosurveillance against squamous cell carcinoma in a novel mouse carcinogenesis model. <i>Carcinogenesis</i> , 2009, 30, 1408-1415.	2.8	33
70	TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment. , 2022, 9, e003134.		32
71	Antibody-based therapy in colorectal cancer. <i>Immunotherapy</i> , 2013, 5, 533-545.	2.0	31
72	Induction of regulatory T cell-resistant helper CD4+ T cells by bacterial vector. <i>Blood</i> , 2008, 111, 1404-1412.	1.4	28

#	ARTICLE	IF	CITATIONS
73	HLA Class I Analysis Provides Insight Into the Genetic and Epigenetic Background of Immune Evasion in Colorectal Cancer With High Microsatellite Instability. <i>Gastroenterology</i> , 2022, 162, 799-812.	1.3	28
74	Induction of CD8 T cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NYESO-1 (NYESO-1 91-110) peptide. <i>International Journal of Cancer</i> , 2013, 132, 345-354.	3.1	27
75	Activities of granulocyte-macrophage colony-stimulating factor and interleukin-3 on monocytes. <i>American Journal of Hematology</i> , 2004, 75, 179-189.	4.1	25
76	Tax is a potential molecular target for immunotherapy of adult T cell leukemia/lymphoma. <i>Cancer Science</i> , 2012, 103, 1764-1773.	3.9	23
77	Effector Regulatory T Cells Reflect the Equilibrium between Antitumor Immunity and Autoimmunity in Adult T-cell Leukemia. <i>Cancer Immunology Research</i> , 2016, 4, 644-649.	3.4	23
78	Efficient ex vivo generation of dendritic cells from CD14+ blood monocytes in the presence of human serum albumin for use in clinical vaccine trials. <i>British Journal of Haematology</i> , 2001, 114, 681-689.	2.5	22
79	<i>Vescimonas</i> gen. nov., <i>Vescimonas coprocola</i> sp. nov., <i>Vescimonas fastidiosa</i> sp. nov., <i>Pusillimonas</i> gen. nov. and <i>Pusillimonas faecalis</i> sp. nov. isolated from human faeces. <i>International Journal of Systematic and Evolutionary Microbiology</i> , 2021, 71, .	1.7	21
80	Hypomethylation of the Treg-Specific Demethylated Region in <i>FOXP3</i> Is a Hallmark of the Regulatory T-cell Subtype in Adult T-cell Leukemia. <i>Cancer Immunology Research</i> , 2016, 4, 136-145.	3.4	20
81	Enhanced tumor response to radiotherapy after PD-1 blockade in metastatic gastric cancer. <i>Gastric Cancer</i> , 2020, 23, 893-903.	5.3	20
82	Engineering strategies for broad application of TCR-T- and CAR-T-cell therapies. <i>International Immunology</i> , 2021, 33, 551-562.	4.0	20
83	TAS-116 (Pimipib), an Oral HSP90 Inhibitor, in Combination with Nivolumab in Patients with Colorectal Cancer and Other Solid Tumors: An Open-Label, Dose-Finding, and Expansion Phase Ib Trial (EPOC1704). <i>Clinical Cancer Research</i> , 2021, 27, 6709-6715.	7.0	20
84	De novo CD5-positive Diffuse Large B-cell Lymphoma of the Temporal Bone Presenting with an External Auditory Canal Tumor. <i>Internal Medicine</i> , 2006, 45, 733-737.	0.7	19
85	UV irradiation of immunized mice induces type 1 regulatory T cells that suppress tumor antigen specific cytotoxic T lymphocyte responses. <i>International Journal of Cancer</i> , 2011, 129, 1126-1136.	5.1	19
86	Cancer immunotherapy with PI3K and PD-1 dual-blockade via optimal modulation of T cell activation signal. , 2021, 9, e002279.		19
87	Editors' Choice Meddling with meddlers: curbing regulatory T cells and augmenting antitumor immunity. <i>Nagoya Journal of Medical Science</i> , 2019, 81, 1-18.	0.3	18
88	A multicenter, open-label, single-arm phase I trial of neoadjuvant nivolumab monotherapy for resectable gastric cancer. <i>Gastric Cancer</i> , 2022, 25, 619-628.	5.3	18
89	Potentiality of multiple modalities for single-cell analyses to evaluate the tumor microenvironment in clinical specimens. <i>Scientific Reports</i> , 2021, 11, 341.	3.3	17
90	Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer. <i>JCI Insight</i> , 2021, 6, .	5.0	17

#	ARTICLE	IF	CITATIONS
91	Meflin-positive cancer-associated fibroblasts enhance tumor response to immune checkpoint blockade. <i>Life Science Alliance</i> , 2022, 5, e202101230.	2.8	16
92	Antibody to CMRF35-Like Molecule 2, CD300e A Novel Biomarker Detected in Patients with Fulminant Type 1 Diabetes. <i>PLoS ONE</i> , 2016, 11, e0160576.	2.5	15
93	Analysis of the Tumor Reactivity of Tumor-Infiltrating Lymphocytes in a Metastatic Melanoma Lesion that Lost Major Histocompatibility Complex Class I Expression after Anti-PD-1 Therapy. <i>Journal of Investigative Dermatology</i> , 2019, 139, 1490-1496.	0.7	15
94	Classification of idiopathic interstitial pneumonias using anti-myxovirus resistance-protein 1 autoantibody. <i>Scientific Reports</i> , 2017, 7, 43201.	3.3	14
95	HSP90 inhibition overcomes EGFR amplification-induced resistance to third-generation EGFR TKIs. <i>Thoracic Cancer</i> , 2021, 12, 631-642.	1.9	14
96	Novel anti-GARP antibody DS-1055a augments anti-tumor immunity by depleting highly suppressive GARP+ regulatory T cells. <i>International Immunology</i> , 2021, 33, 435-446.	4.0	14
97	Clinicopathological, genomic and immunological features of hyperprogressive disease during PD-1 blockade in gastric cancer patients. <i>Journal of Clinical Oncology</i> , 2018, 36, 4106-4106.	1.6	14
98	Genomic determinants impacting the clinical outcome of mogamulizumab treatment for adult T-cell leukemia/lymphoma. <i>Haematologica</i> , 2022, 107, 2418-2431.	3.5	14
99	Human bone marrow stromal cells simultaneously support B and T/NK lineage development from human haematopoietic progenitors: a principal role for flt3 ligand in lymphopoiesis. <i>British Journal of Haematology</i> , 2012, 157, 674-686.	2.5	12
100	Adult-Onset Anti-Citrullinated Peptide Antibody-Negative Destructive Rheumatoid Arthritis Is Characterized by a Disease-Specific CD8+ T Lymphocyte Signature. <i>Frontiers in Immunology</i> , 2020, 11, 578848.	4.8	11
101	Depletion of central memory CD8+ T cells might impede the antitumor therapeutic effect of Mogamulizumab. <i>Nature Communications</i> , 2021, 12, 7280.	12.8	11
102	Model-based cell clustering and population tracking for time-series flow cytometry data. <i>BMC Bioinformatics</i> , 2019, 20, 633.	2.6	10
103	The potential application of PD-1 blockade therapy for early-stage biliary tract cancer. <i>International Immunology</i> , 2020, 32, 273-281.	4.0	10
104	Suppression from beyond the grave. <i>Nature Immunology</i> , 2017, 18, 1285-1286.	14.5	10
105	The ratio of CD8+ lymphocytes to tumor-infiltrating suppressive FOXP3+ effector regulatory T cells is associated with treatment response in invasive breast cancer. <i>Discover Oncology</i> , 2022, 13, 27.	2.1	10
106	Identification of Novel and Noninvasive Biomarkers of Acute Cellular Rejection After Liver Transplantation by Protein Microarray. <i>Transplantation Direct</i> , 2016, 2, e118.	1.6	9
107	Regulatory T cells, as a target in anticancer immunotherapy. <i>Immunotherapy</i> , 2017, 9, 623-627.	2.0	9
108	Overcoming regulatory T cell suppression by a lyophilized preparation of <i>Streptococcus pyogenes</i> . <i>European Journal of Immunology</i> , 2013, 43, 989-1000.	2.9	8

#	ARTICLE	IF	CITATIONS
109	Endoscopic Activity and Serum TNF- α Level at Baseline Are Associated With Clinical Response to Ustekinumab in Crohn's Disease Patients. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 1669-1681.	1.9	8
110	Updated Efficacy Outcomes of Anti-PD-1 Antibodies plus Multikinase Inhibitors for Patients with Advanced Gastric Cancer with or without Liver Metastases in Clinical Trials. <i>Clinical Cancer Research</i> , 2022, 28, 3480-3488.	7.0	8
111	Immunosuppressive tumor microenvironment of usual interstitial pneumonia-associated squamous cell carcinoma of the lung. <i>Journal of Cancer Research and Clinical Oncology</i> , 2018, 144, 835-844.	2.5	7
112	Report on the use of non-clinical studies in the regulatory evaluation of oncology drugs. <i>Cancer Science</i> , 2016, 107, 189-202.	3.9	6
113	Phase Ib study on the humanized anti-CCR4 antibody, KW-0761, in advanced solid tumors.. <i>Nagoya Journal of Medical Science</i> , 2021, 83, 827-840.	0.3	6
114	NY-ESO-1 protein glycosylated by yeast induces enhanced immune responses. <i>Yeast</i> , 2010, 27, 919-931.	1.7	5
115	Overview: New Modality for Cancer Treatment. <i>Oncology</i> , 2015, 89, 33-35.	1.9	5
116	Study protocol for JCOG1807C (DEEP OCEAN): a interventional prospective trial to evaluate the efficacy and safety of durvalumab before and after operation or durvalumab as maintenance therapy after chemoradiotherapy against superior sulcus non-small cell lung cancer. <i>Japanese Journal of Clinical Oncology</i> , 2022, 52, 383-387.	1.3	5
117	Newly emerged immunogenic neoantigens in established tumors enable hosts to regain immunosurveillance in a T-cell-dependent manner. <i>International Immunology</i> , 2021, 33, 39-48.	4.0	4
118	Regulatory T cells in cancer; can they be controlled?. <i>Immunotherapy</i> , 2015, 7, 843-846.	2.0	3
119	Regulatory T Cell as a Biomarker of Treatment-Free Remission in Patients with Chronic Myeloid Leukemia. <i>Cancers</i> , 2021, 13, 5904.	3.7	3
120	Isolation of tumor-infiltrating lymphocytes from preserved human tumor tissue specimens for downstream characterization. <i>STAR Protocols</i> , 2022, 3, 101557.	1.2	3
121	Characterization of the tumor immune-microenvironment of lung adenocarcinoma associated with usual interstitial pneumonia. <i>Lung Cancer</i> , 2018, 126, 162-169.	2.0	2
122	Tyrosine Kinase Inhibitor Imatinib Enhances Tumor Immunity By Depleting Functionally Mature Regulatory T Cells. <i>Blood</i> , 2015, 126, 2219-2219.	1.4	2
123	Mixed Response to Cancer Immunotherapy is Driven by Intratumor Heterogeneity and Differential Interlesion Immune Infiltration. <i>Cancer Research Communications</i> , 2022, 2, 739-753.	1.7	2
124	Comprehensive exploration of autoantibody in Behçet's disease: A novel autoantibody to claudin-1, an essential protein for tight junctions, is identified. <i>Joint Bone Spine</i> , 2014, 81, 546-548.	1.6	1
125	Flow cytometry analysis of peripheral Tregs in patients with multiple myeloma under lenalidomide maintenance. <i>International Journal of Hematology</i> , 2021, 113, 772-774.	1.6	1
126	CYBERTRACK2.0: zero-inflated model-based cell clustering and population tracking method for longitudinal mass cytometry data. <i>Bioinformatics</i> , 2021, 37, 1632-1634.	4.1	1

#	ARTICLE	IF	CITATIONS
127	Regulatory T cells as a target of cancer immunotherapy. <i>Annals of Oncology</i> , 2016, 27, vii3.	1.2	0
128	Analysis of CCR4-expressing T cells in patients with rhododendol-induced leukoderma. <i>Journal of Dermatological Science</i> , 2016, 84, e13.	1.9	0
129	Possible Biomarker for immune checkpoint inhibitor. <i>Annals of Oncology</i> , 2017, 28, ix20.	1.2	0
130	A simple method to distinguish residual elotuzumab from monoclonal paraprotein in immunofixation assays for multiple myeloma patients. <i>International Journal of Hematology</i> , 2021, 113, 473-479.	1.6	0
131	Kinetics of Regulatory T Cells Predict the Recurrence of CML after Stopping Imatinib in Japanese CML Patients. <i>Blood</i> , 2016, 128, 4240-4240.	1.4	0
132	Clinical Impact of Pre-Transplant Microbial Diversity on Transplant Outcomes. <i>Blood</i> , 2016, 128, 4577-4577.	1.4	0
133	Regulatory-T cells (Tregs) in tumor infiltrating lymphocytes (TILs) from patients with advanced gastric cancer (AGC) after chemotherapy containing ramucirumab.. <i>Journal of Clinical Oncology</i> , 2017, 35, e15570-e15570.	1.6	0
134	<i>Internal Medicine</i> , 2019, 108, 430-437.	0.0	0
135	Optimum Imatinib Exposure Have Possibility of Leading to Appropriate Immune Response after Imatinib Discontinuation in CML Patients. <i>Blood</i> , 2019, 134, 192-192.	1.4	0
136	Correlation between Changes in Granzyme B Expression and Time to Progression in Patients with Newly Diagnosed Multiple Myeloma Treated with Lenalidomide and Dexamethasone Therapy. <i>Blood</i> , 2019, 134, 1792-1792.	1.4	0